Erasca Inc. (NASDAQ:ERAS) is one of the 10 Stocks Delivering Eye-Popping Gains.
Erasca snapped a four-day losing streak on Thursday, soaring 16.90 percent to close at $10.65 apiece, as investors resorted to bargain-hunting following a steep plunge in the previous trading days, with sentiment fueled by renewed optimism for its cancer treatment candidate.
It can be recalled that shares of Erasca Inc. (NASDAQ:ERAS) fell sharply in the past few days following the confirmation of the death of a patient previously enrolled in the first phase of clinical study for its treatment candidate, ERAS-0015.
Photo by Roger Brown on Pexels
In a call with analysts, the company said that a 66-year-old man succumbed after electing to withdraw supportive care during the trial after developing Grade 3 pneumonitis on 24 mg.
Erasca Inc. (NASDAQ:ERAS), however, deemed the case a “rare event.”
Despite the incident, Erasca Inc. (NASDAQ:ERAS) maintained ERAS-0015 as potentially the best-in-class amid positive preliminary data from the first phase across all other enrolled patients.
According to the company, ERAS-0015 demonstrated favorable response rates, with more than half of enrolled lung cancer patients seeing their tumors shrink, and around 50 percent of pancreatic cancer patients saw shrinkage.
ERAS-0015 also demonstrated a favorable safety profile and recorded only low-grade adverse events.
“We are thrilled with the robust efficacy results demonstrated so far by our pan-RAS inhibitor ERAS-0015 in patients with lung and pancreatic cancer. The magnitude of clinical benefit seen during dose escalation is particularly striking and compares favorably with other pan-RAS, pan-KRAS, or KRAS-mutant selective inhibitors,” said Erasca Inc. (NASDAQ:ERAS) Chairman and CEO Jonathan Lim.
“Notably, preliminary data support ERAS-0015 may be combined with standard-of-care doses of panitumumab, positioning it as a potential backbone therapy for future combination regimens. Together, we believe these findings support the best-in-class potential of ERAS-0015, and we look forward to continued progress in our Phase 1 monotherapy dose expansion cohorts and combination dose escalation cohorts,” he noted.
While we acknowledge the risk and potential of ERAS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ERAS and that has 10,000% upside potential, check out our report about the cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
